Microbiome testing in gastrointestinal cancers: From microbial signatures to clinical translation
Best Practice & Research Clinical Gastroenterology · 2026-08 · 83 · 102127
DOI: 10.1016/j.bpg.2026.102127 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026-08. Verfasst von Darja Nikitina und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Gastrointestinal Microbiome, Dysbiosis. Die Arbeit nennt 103 Literaturangaben. Gefördert von: European Commission.
Abstract (Originalsprache)
The gastrointestinal microbiome has emerged as a critical interface between environmental exposures and host biology, shaping carcinogenesis, tumor behavior, and therapeutic responsiveness across digestive tract malignancies. This narrative review synthesizes current evidence on microbiome testing in esophageal, gastric, colorectal, hepatobiliary, pancreatic, and gastrointestinal stromal cancers, highlighting microbial signatures, emerging translational applications, and the methodological challenges that currently limit clinical implementation. Tumor-specific microbial alterations are considered alongside the broader functional consequences of dysbiosis, including its roles in genotoxicity, immune modulation, and metabolic reprogramming. Particular attention is given to the influence of the microbiome on systemic therapies, especially immune checkpoint inhibition, where microbial diversity, compositional signatures, and antibiotic exposure have been associated with differences in treatment efficacy. Emerging mechanistic insights are highlighted, including the role of microbiota-derived metabolites as key mediators of host-tumor immune interactions. The review further discusses microbiome-directed interventions, including fecal microbiota transplantation and dietary modulation, while critically evaluating the barriers to their clinical translation. Although microbiome profiling has considerable potential to improve risk stratification and therapeutic personalization, current evidence remains largely associative or based on early-phase clinical studies, and no microbiome-based testing strategy has yet been validated for routine clinical use beyond Helicobacter pylori eradication for gastric cancer prevention. Large prospective studies, standardized methodologies, and interventional clinical trials are required before microbiome testing can be integrated into routine precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
- Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania; Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
- Department of Anesthesiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
- Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
- Department of Laboratory Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania.
- Department of Pathology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Förderung
- European Commission
Zitieren
APA
Nikitina, D., Morkunas, E., Sabanas, P., Jonaitis, P., Urbonas, T., Gedgaudiene, G., Gedgaudas, R., Kupcinskiene, K., Macas, A., Simenas, S., Kiudelyte, D., Buginyte, R., Vitkauskiene, A., Poskiene, L., Strati, F., Skieceviciene, J., & Kupcinskas, J. (2026). Microbiome testing in gastrointestinal cancers: From microbial signatures to clinical translation. Best Practice & Research Clinical Gastroenterology, 83, 102127. https://doi.org/10.1016/j.bpg.2026.102127
Vancouver
Nikitina D, Morkunas E, Sabanas P, Jonaitis P, Urbonas T, Gedgaudiene G, et al. Microbiome testing in gastrointestinal cancers: From microbial signatures to clinical translation. Best Practice & Research Clinical Gastroenterology. 2026;83:102127. doi:10.1016/j.bpg.2026.102127
BibTeX
@article{Nikitina2026,
author = {Nikitina, Darja and Morkunas, Egidijus and Sabanas, Povilas and Jonaitis, Paulius and Urbonas, Tadas and Gedgaudiene, Greta and Gedgaudas, Rolandas and Kupcinskiene, Kristina and Macas, Andrius and Simenas, Sarunas and Kiudelyte, Dovile and Buginyte, Roberta and Vitkauskiene, Astra and Poskiene, Lina and Strati, Francesco and Skieceviciene, Jurgita and Kupcinskas, Juozas},
title = {Microbiome testing in gastrointestinal cancers: From microbial signatures to clinical translation},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2026},
volume = {83},
pages = {102127},
doi = {10.1016/j.bpg.2026.102127}
}
EUVIMED